腹主动脉瘤腔内修复术前输血风险评分以避免血型交叉配血
该研究基于NSQIP数据库2011至2015年4875例择期肾下腹主动脉瘤EVAR患者,构建并验证术后24小时内输血风险模型。输血率仅4.5%且逐年下降,独立预测因素包括术前红细胞压积<36%、主动脉直径、依赖功能状态和COPD。评分<3/9分(输血概率<5%)可使86%患者避免术前血型交叉配血。
要点
- 择期肾下EVAR术后24小时内输血率仅4.5%,且从2011年6.5%降至2015年3.2%。
- 术前红细胞压积<36%、主动脉直径每增1cm、依赖功能状态和COPD与输血独立相关。
- 风险评分<3/9分对应输血概率<5%,可使86%患者避免术前血型交叉配血。
核心结论
- EVAR围术期输血越来越少见,输血风险评分或单纯红细胞压积<36%即可较好预测输血。
- 应用该风险评分可使多数患者避免不必要的术前血型交叉配血,节省时间和成本。
研究设计与样本
- 回顾性队列研究,查询NSQIP靶向血管模块2011至2015年所有择期EVAR病例。
- 仅纳入肾下腹主动脉瘤,排除破裂动脉瘤和术前72小时内输血患者。
- 共4875例患者,三分之二随机分配至模型推导队列,三分之一至验证队列。
- 使用逻辑回归构建并验证术后24小时内(含术中)输血风险模型。
主要发现
- 4875例择期肾下EVAR中仅221例(4.5%)在术后24小时内接受输血。
- 输血频率从2011年6.5%单调下降至2015年3.2%。
- 术前红细胞压积<36%与输血独立相关(OR 3.4,95%CI 2.1-5.4,P<.001)。
- 主动脉直径每增加1cm与输血独立相关(OR 1.2,95%CI 1.03-1.4,P=.02)。
- 术前依赖功能状态(OR 2.5,95%CI 1.1-5.5,P=.03)和COPD(OR 1.7,95%CI 1.04-2.9,P=.04)与输血独立相关。
关键数值与推荐
- 风险评分<3/9分对应输血概率<5%,可避免术前血型交叉配血。
- 术前红细胞压积<36%是输血独立预测因素(OR 3.4,95%CI 2.1-5.4,P<.001)。
临床怎么用
- 对择期肾下EVAR患者术前可计算输血风险评分,评分<3/9分者仅备血型筛查而非交叉配血。
- 术前红细胞压积>36%且评分低者输血概率极低,可安全省略交叉配血。
局限性
- 原文未报告具体局限性内容。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Preoperative type and cross are often routinely ordered before elective endovascular aneurysm repair (EVAR), but the cost of this practice is high, and transfusion is rare. We therefore aimed to stratify patients by their risk of transfusion to identify a cohort in whom a type and screen would be sufficient. METHODS: We queried the targeted vascular module of the National Surgical Quality Improvement Program (NSQIP) for all elective EVARs from 2011 to 2015. We included only infrarenal aneurysms and excluded ruptured aneurysms and patients transfused within 72 hours preoperatively. Two-thirds of the cases were randomly assigned to a model derivation cohort and one third to a validation cohort. We created and subsequently validated a risk model for transfusion within the first 24 hours of surgery (including intraoperatively), using logistic regression. RESULTS: Between 2011 and 2015, there were 4875 patients who underwent elective infrarenal EVAR, only 221 (4.5%) of whom received a transfusion within 24 hours of surgery. The frequency of transfusion during the study period declined monotonously from 6.5% in 2011 to 3.2% in 2015. The factors independently associated with transfusion were preoperative hematocrit <36% (odds ratio [OR], 3.4 [95% confidence interval, 2.1-5.4]; P < .001), aortic diameter (per centimeter increase: OR, 1.2 [1.03-1.4]; P = .02), preoperative dependent functional status (OR, 2.5 [1.1-5.5]; P = .03), and chronic obstructive pulmonary disease (OR, 1.7 [1.04-2.9]; P = .04). A risk prediction model based on these criteria produced a C statistic of 0.69 in the prediction cohort and 0.76 in the validation cohort and a Hosmer-Lemeshow goodness of fit of 0.62 and 0.14, respectively. A score of <3 of 9, corresponding to a <5% probability of transfusion, would avoid preoperative type and cross in 86% of patients. Of the 4203 patients (86%) with a hematocrit >36%, only 6 (0.1%) had a risk score of >3. CONCLUSIONS: Perioperative transfusion for EVAR is becoming increasingly uncommon and is predicted well by a transfusion risk score or simply a hematocrit of <36%. Application of this risk score would avoid unnecessary type and cross in the majority of patients, leading to significant savings in both time and cost.
引用
- O'Donnell TFX, Shean KE, Deery SE, et al. A preoperative risk score for transfusion in infrarenal endovascular aneurysm repair to avoid type and cross. J Vasc Surg. 2017. PMID: 28756046. doi:10.1016/j.jvs.2017.05.108
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。